NCT05923684 NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making
| NCT ID | NCT05923684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-11-15 |
| Primary Completion | 2026-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-11-15 with a primary completion date of 2026-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigators will report the top five sentences from each consultation across key content areas (cancer prognosis, life expectancy, erectile dysfunction, urinary incontinence, and irritative urinary symptoms) to both patients and physicians within 2 weeks of the consultation.
Eligibility Criteria
Inclusion Criteria: 1. Men undergoing initial treatment consultation for clinically localized prostate cancer; 2. Men with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy. 3. Cedars-Sinai patient. 4. Ability to read and write in English. Exclusion Criteria: 1. Under 18 years of age; 2. Subjects with difficulty communicating or dementia; 3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English; 4. Men with locally advanced or metastatic prostate cancer; 5. Men who have already been treated for clinically localized prostate cancer
Contact & Investigator
Timothy Daskivich
PRINCIPAL INVESTIGATOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT05923684 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05923684 currently recruiting?
Yes, NCT05923684 is actively recruiting participants. Contact the research team at timothy.daskivich@cshs.org for enrollment information.
Where is the NCT05923684 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT05923684 clinical trial?
NCT05923684 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Timothy Daskivich at Cedars-Sinai Medical Center. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.